Testing the Boundaries
Are you compliant with the new guidelines for elemental impurities? There are only six months left to get up to speed.
Sarah James |
In June 2016, the FDA announced new draft guidance on reducing elemental impurities in drug products. Elemental impurities can make their way into a drug product from various points in manufacturing processes – and in some cases can be a risk to patients. The aim of the guidance is to help manufacturers of both new and generic small-molecule drugs to comply with recent standards introduced by the International Council for Harmonization (ICH) and US Pharmacopeial Convention (USP). These standards, which are established in USP General Chapters <232> Elemental Impurities – Limits, and <233> Elemental Impurities – Procedures, as well as ICH Q3D – Guideline for Elemental Impurities, come into full effect at the start of 2018 and place drug elemental impurities into various new hazard categories based on their toxicity (permitted daily exposure [PDE]) and likelihood of occurrence in the drug product, which is derived from a number of factors including probability of use in pharmaceutical processes, probability of being a co-isolated impurity with other elemental impurities in materials used in pharmaceutical processes, and the observed natural abundance of the element.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.